Puricore remains at an interesting juncture in its development as it transitions to a fully fledged drug development company based on leveraging its proprietary immunomodulatory technology to develop novel, topical treatments for inflammatory diseases. The Supermarket Retail division, now deemed non-core, delivered a strong revenue performance but still requires investment support. As such options are being considered that could drive further growth and generate shareholder value.